Skip to main content
BXPHF logo

Botanix Pharmaceuticals Limited (BXPHF) Stock Price & Analysis

Botanix Pharmaceuticals Limited (BXPHF) — price $0.0048 (0.00%), as of the Nov 19, 2026 trading session; market cap $13.3M.

Educational signal · not a buy or sell recommendation · How to read this

$0.0048 $0.00 (0.00%) Market Cap $13.3M

Botanix Pharmaceuticals Limited · BXPHF

Botanix Pharmaceuticals Limited is an Australian company focused on the research and development of dermatology and antimicrobial products. Their pipeline includes treatments for acne, rosacea, hyperhidrosis, and staphylococcus aureus infections.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RLYB · Rallybio Corporation · 82 /100
  • ICCC · ImmuCell Corporation · 82 /100
  • ORMP · Oramed Pharmaceuticals Inc. · 72 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.0048
Change on the day0.00%
52-week range$0.0048 – $0.1149
Market capitalisation$13.3M
Shares traded on the day100.0K

Price & events

Other perspectives

Council score for Botanix Pharmaceuticals (BXPHF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Sep 29, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Moderate
ROE Negative
Gross Margin Negative

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Botanix Pharmaceuticals (BXPHF), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Botanix Pharmaceuticals Limited (BXPHF) is the company analyzed here. It employs 11 people and is led by Howie McKibbon. In Q4 FY2026 it reported revenue of A$18M and net income of -A$37M. The market values it at $13.3M.

2 · Latest results

What do the latest results show for Botanix Pharmaceuticals (BXPHF)?

Short answer · as of

The most recent reported quarter, Q4 FY2026, carried revenue of A$18M. Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q4 FY2026A$18M-A$37M-A$0.02 (diluted)
Q2 FY2026A$16M-A$33M-A$0.02 (diluted)
Q4 FY2025A$5M-A$56M-A$0.03 (diluted)
Q2 FY2025A$377,597-A$31M-A$0.02 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Botanix Pharmaceuticals (BXPHF)?

Short answer · as of

The distress and quality screens read Altman Z -4.26 · Piotroski F 3. Trailing ratios: ROA -65.8% · current ratio 2.59.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -4.26 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 4 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held BXPHF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported BXPHF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Common Questions About BXPHF

These answers are editorial: 1 of these 1 answer is drawn from the BXPHF research dossier (written Mar 17, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.

What are the main risks for BXPHF?

The main risks for Botanix Pharmaceuticals Limited include the potential for unsuccessful clinical trial outcomes, regulatory hurdles and delays in obtaining approvals, and competition from other pharmaceutical companies.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 8 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.